IMGO Imago BioSciences Inc.

18.32
+1.42  (+8%)
Previous Close 16.9
Open 16.98
52 Week Low 14.99
52 Week High 19.945
Market Cap $611,442,000
Shares 33,375,655
Float 26,402,562
Enterprise Value $481,308,569
Volume 78,086
Av. Daily Volume 78,889
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Bomedemstat
Myelofibrosis
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Bomedemstat
Essential Thrombocythemia
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Bomedemstat and ruxolitinib
Myelofibrosis
Phase 2
Phase 2
Phase 2 trial planned.
Bomedemstat
Polycythemia Vera
Phase 2
Phase 2
Phase 2 trial enrolling.

Latest News

  1. Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has granted orphan designation for bomedemstat, a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of essential thrombocythemia (ET).

    "As a company dedicated to providing new, safe and effective treatment alternatives for patients with life-threatening diseases of the bone marrow, we are pleased to receive EMA orphan designation for our lead asset, which provides meaningful validation for our treatment approach," said Hugh Young Rienhoff, Jr., M.D., chief executive officer of Imago BioSciences.

    Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has granted orphan designation for bomedemstat, a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of essential thrombocythemia (ET).

    "As a company dedicated to providing new, safe and effective treatment alternatives for patients with life-threatening diseases of the bone marrow, we are pleased to receive EMA orphan designation for our lead asset, which provides meaningful validation for our treatment approach," said Hugh Young Rienhoff, Jr., M.D., chief executive officer of Imago BioSciences.

    Data presented at the 26th European Hematology Association Virtual Congress showed that bomedemstat was generally well-tolerated by patients with ET and demonstrated promising clinical activity as a monotherapy in patients who have become resistant to or intolerant of one or more standard-of-care treatments. The Phase 2 clinical trial of bomedemstat for the treatment of ET continues to actively enroll globally (NCT04254978).

    "Gaining this designation is an important regulatory milestone that gives us added momentum in advancing the development of bomedemstat. We are planning a pivotal study to address the significant medical needs of these patients," said Wan-Jen Hong, M.D., chief medical officer of Imago BioSciences.

    Orphan designation by the EMA is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions affecting no more than five in 10,000 people in the European Union. Medicines that meet the criteria for orphan designation potentially qualify for several incentives, including 10-year market exclusivity, protocol assistance, and reduced fees for regulatory activities.

    About Essential Thrombocythemia

    Essential thrombocythemia is a rare blood cancer resulting from the overproduction of platelets, which increases the risk of blood clots and bleeding. It is one of the MPN family of rare bone marrow diseases and affects approximately 80,000 – 100,000 patients in the U.S. There is a significant unmet need for new ET therapies that can effectively reduce patient platelet levels without general bone marrow suppression, while slowing the progression of the underlying disease. By normalizing elevated platelets, the primary clinical feature of ET, bomedemstat can address an unmet need in the 20% of the high-risk ET patients who are intolerant or resistant to hydroxyurea, the current standard-of-care for those patients with ET at greatest risk for blood clots.

    About Imago BioSciences

    Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.

    Forward Looking Statements

    This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "may," "will," "should," "expect," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

    These statements may relate to, but are not limited to, the results, conduct, progress and timing of Imago clinical trials, the regulatory approval path for bomedemstat, expectations of future operating results or financial performance, market size and growth opportunities, plans for future operations, competitive position, technological capabilities, and strategic relationships, as well as assumptions relating to the foregoing. Forward looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. You should not put undue reliance on any forward-looking statements. Forward looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.

    Except as required by law, Imago does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

    View Full Article Hide Full Article
  2. Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common stock, the underwriters have exercised their option to purchase an additional 1,260,000 shares of common stock from the Company. The gross proceeds from the exercise of the option, before deducting underwriting discounts and commissions and other offering expenses payable by Imago, were approximately $20.2 million.

    Jefferies, Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.

    A registration statement relating to the securities has…

    Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common stock, the underwriters have exercised their option to purchase an additional 1,260,000 shares of common stock from the Company. The gross proceeds from the exercise of the option, before deducting underwriting discounts and commissions and other offering expenses payable by Imago, were approximately $20.2 million.

    Jefferies, Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.

    A registration statement relating to the securities has been filed with the Securities and Exchange Commission and became effective on July 15, 2021. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at or by phone at 877-821-7388; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at ; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    View Full Article Hide Full Article
  3. Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds from its previously announced initial public offering and $20.0 million in gross proceeds from its concurrent private placement.

    The initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share resulted in aggregate gross proceeds to Imago of $134.4 million, before deducting underwriting discounts, commissions and offering expenses. All of the shares in the initial public offering were offered by Imago.

    Imago's common stock is now listed on The Nasdaq Global…

    Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds from its previously announced initial public offering and $20.0 million in gross proceeds from its concurrent private placement.

    The initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share resulted in aggregate gross proceeds to Imago of $134.4 million, before deducting underwriting discounts, commissions and offering expenses. All of the shares in the initial public offering were offered by Imago.

    Imago's common stock is now listed on The Nasdaq Global Select Market under the ticker symbol "IMGO".

    Jefferies, Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.

    A registration statement relating to the securities has been filed with the Securities and Exchange Commission and became effective on July 15, 2021. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at or by phone at 877-821-7388; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at ; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    View Full Article Hide Full Article
  4. Imago BioSciences, Inc. ("Imago"), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option to purchase from Imago up to an additional 1,260,000 shares…

    Imago BioSciences, Inc. ("Imago"), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option to purchase from Imago up to an additional 1,260,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Imago's common stock has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading under the symbol "IMGO" on July 16, 2021. The offering is expected to close on July 20, 2021, subject to satisfaction of customary closing conditions.

    Jefferies, Cowen, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.

    A registration statement relating to the securities has been filed with the Securities and Exchange Commission and became effective on July 15, 2021. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at or by phone at 877-821-7388; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at ; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    View Full Article Hide Full Article
View All Imago BioSciences Inc. News